Compania farmaceutică Sandoz continuă discuţiile cu autorităţile americane, după ce Donald Trump a amenințat cu taxe vamale ridicate

Swiss generic drug manufacturer Sandoz is continuing discussions with U.S. authorities following President Trump's tariff threats on pharmaceutical imports. Trump stated that generic drug producers must manufacture locally or face significant tariffs starting in 2028. Sandoz aims to improve drug accessibility in the U.S. but plans to close its only U.S. production facility by 2026. Analysts suggest that U.S. regulations could increase generic drug prices and impact production in countries like China and India, affecting Sandoz's sales in North America. Sandoz's shares fell by about 3% in Zurich.